216 / 1840
IGR phase III trial
CONCLUSIONS :
Cs 37 cGy/h versus 73 cGy/h
• No DRE for surgical difficulties at operation except
for delayed surgery in stage II
• No DRE for tumor sterilisation in specimen except
for medium size tumors
• No DRE for relapse free survical
• Higher complications prevalence in the higher dose
rate group
Haie et al., 1994